Market LIVE
Published markets; coverage varies by country
Product profile · United States

Kimmtrak

 ·  Patent Litigation & Settlement History ↓

Ingredienttebentafusp-tebn
Application typeBLA
Application761228
Product001
Dosage formInjection
RouteIntravenous
Strength100MCG/0.5ML
Approval date2022-01-25
Marketing statusPrescription
Status event—
ApplicantIMMUNOCORE LTD
Product source

Current GenericRadar decision

Year2034
SelectionCANDIDATE
ReviewFINAL_CHECKING
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2034-01-25
Patent anchor2030-07-01
Exclusivity anchor2034-01-25
Protection date2034-01-25
First Final ANDA—
Status event—

GNR judgment: CANDIDATE. Reference year: 2034. Anchor type: REGULATORY_EXCLUSIVITY. Patent anchor: 2030-07-01. Exclusivity anchor: 2034-01-25. Anchor date: 2034-01-25. Patent tail: no. Exclusivity tail: not established. Review status: FINAL_CHECKING. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US85191002030-07-01— —YNTRUE_DS
{"batch":"BLA-05-05","reference_date_only":true,"official_current_term_verified":false,"pending_reason":"OFFICIAL_TERM_PTE_TD_CHECK","scope_review_classification":"TRUE_DS","source_report":"BLA_05_05_50_JUDGMENT_20261021.html"}
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE2022-01-252029-01-25treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma————Source
Orphan Exclusivity Exp. Date—2029-01-25————Source
RPE2022-01-252034-01-25Full-product 12-year operational assumption; not FDA determinationYY——Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
PATENT2030-07-01ANCHOR_REFERENCEProduct scope reviewed; reference date only; current official term verification pendingSource
REGULATORY_EXCLUSIVITY2029-01-25SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2034-01-25ANCHOR_CALCULATIONFirst approval + 12 years; operational assumption, not FDA determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.